Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

requiring outpatient medical management within this population.

The overall incidence and severity of adverse events (AEs) were similar between the motavizumab and the placebo groups in these Native American infants. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of skin reactions were more common following Motavizumab than placebo (by an approximately 2 percent increase in frequency). Motavizumab was otherwise well tolerated.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients). Otherwise healthy infants in some Native American populations have demonstrated rates of RSV hospitalization that are similar to those among children with underlying medical conditions in the general U.S. population.

About Motavizumab

Motavizumab is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
(Date:8/28/2015)... HONG KONG , August 28, 2015 ... Gero in collaboration with one of the leading academics ... Reis (current world record holder in life extension for ... new insights into biology of aging and age-related diseases, primarily, ... networks. The work has just been published as "Stability analysis ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... An article published August 19th by the LA Times ... to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior pizza ... the current process, having already gone on for over a year, is taking much ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... 1, WASHINGTON, May 1 U.S. Paralympian April ... on the track. In September, she,will travel to Beijing ... favored to medal in the 100- and 200-meter dashes. ... well what working,Americans need to do to keep their ...
... notes, "We make,decisions for the right reasons and then we ... the right time, by the right people, and at the,right ... Management has now grown so much that an increasingly,sophisticated system ... and strategic at its core -- but that is fraught ...
... ... HILLS, Ill. and CORPUS CHRISTI, Texas, May 1 ... from Texas,A&M-Corpus Christi,s Kinesiology Department demonstrated the correlation,between improved ... improvement in the hitting performance of,Islander baseball players after ...
... Texas Cardiac Arrhythmia Recruits and Hires Dr. Andrea ... Executive Medical Director of the Texas Cardiac Arrhythmia,Institute ... May 1 St. David,s HealthCare,along with Texas ... Cardiac Arrhythmia Institute (TCAI) at St. David,s Medical ...
... N.C., May 1 The Oregon State,Supreme Court ... statewide class,action in which plaintiff sought to make ... for medical monitoring of all Oregon,cigarette smokers., ... of the complaint and,the intermediate appellate court,s unanimous ...
... hinder a protein called IGF-1 not entirely successful, studies ... idea that prostate cancer can be treated successfully just ... growth factor (IGF-1) has been undermined by two new ... by a number of drug companies and academic researchers, ...
Cached Medicine News:Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 2Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 3Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 4Health News:Best Practices in Designing Effective Brand Teams 2Health News:Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 3Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 4Health News:Complications Found in Proposed Prostate Cancer Treatment 2
Bipolar Atrial "J" Lead...
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: